NICE Technology Assessment Reviews (TAR)

Overview

Contact: Stephen Palmer

The NIHR Technology Assessment Reviews (TAR) programme enables rapid commissioning of economic evaluations and health technology assessments (HTA) to inform the National Institute for Health and Care Excellence (NICE) and other policy makers.

Our applied work in this programme supports the role of NICE in improving outcomes for people using the NHS and other public health and social care services by ensuring national guidance is underpinned by rigorous and independent assessments of clinical effectiveness and value for money. Our broader methodological research also aims to inform the processes and methods applied by NICE and continues to evolve in response to key policy initiatives.

The process of systematically assessing and combining clinical and economic evidence to inform policy decisions brings economics together with other disciplines such as clinical epidemiology, statistics and information specialists. The TAR programme at York is held jointly between CHE and the Centre for Reviews and Dissemination (CRD).

In addition, CHE is part of the NICE Decision Support Unit (DSU), a collaborative group which also involves colleagues at the Universities of Sheffield and Leicester. The DSU is commissioned by NICE to provide a research and training resource.

Publications

2018

Peron M, Llewellyn A, Moe-Byrne T, Walker S, Walton M, Harden M, Palmer S, Simmonds M. Adjunctive colposcopy technologies for assessing suspected cervical  abnormalities: Systematic reviews and economic evaluation. Health Technology Assessment 2018;22(54).

Phillippo D, Ades T, Dias S, Palmer S, Abrams K, Welton NJ. Methods for population-adjusted indirect comparisons in Health Technology Appraisal. Medical Decision Making 2018;38(2):200-211.

Saramago Goncalves P, Yang H, Llewellyn A, Palmer SJ, Simmonds MC, Griffin S. High-throughput, non-invasive prenatal testing for fetal RHD genotype to guide antenatal prophylaxis with anti-D immunoglobulin: a cost-effectiveness analysis. BJOG An International Journal of Obstetrics and Gynaecology 2018;125(11):1414-1422.  

Saramago Goncalves P, Yang H, Llewellyn A, Walker R, Harden M, Palmer SGriffin S, Simmonds M.High-throughput non-invasive prenatal testing for fetal rhesus D status in RhD-negative women not known to be sensitised to the RhD antigen: a systematic review and economic evaluation. Health Technology Assessment 2018;22(13):1-172.

South E, Cox E, Meader N, Woolacott N, Griffin S. Strimvelis® for treating severe combined immunodeficiency caused by adenosine deaminase deficiency: An evidence review group perspective of a NICE highly specialised technology evaluation. Pharmacoeconomics - Open 2018;doi: 10.1007/s41669-018-0102-3.

Wade R, Grosso A, South E, Rothery CSaramago PSchmitt L, Wright K, Palmer S. Brodalumab for the treatment of moderate to severe plaque psoriasis: an Evidence Review Group evaluation of a NICE Single Technology Appraisal. Pharmacoeconomics 2018;doi:10.1007/s40273-018-0698-2.

2017

Corbett M, Chehadah F, Biswas M, Moe-Byrne T, Palmer S, Soares M, Walton M, Harden M, Ho P, Woolacott N, Bojke L. Certolizumab pegol and secukinumab for treating active psoriatic arthritis following inadequate response to disease-modifying antirheumatic drugs: a systematic review and economic evaluation. Health Technology Assessment 2017;21(56):1-326.

Duarte A, Mebrahtu T, Saramago Goncalves P, Harden M, Murphy R, Palmer S, Woolacott N, Rodgers M, Rothery C. Adalimumab, etanercept and ustekinumab for treating plaque psoriasis in children and young people: systematic review and economic evaluation. Health Technology Assessment 2017;21(64):1-244.

Hettle R, Corbett M, Hinde S, Hodgson R, Jones-Diette J, Woolacott N, Palmer S. The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal. Health Technology Assessment 2017;21(7):1-238.

Woods B, Sideris E, Palmer S, Latimer N, Soares M. NICE DSU technical support document 19: Partitioned survival analysis for decision modelling in health care: a critical review. 2 Jun 2017, NICE Decision Support Unit;72p.

2016

Corbett M, Soares M, Jhuti G, Rice S, Spackman E, Sideris E, Moe-Byrne T, Fox D, Marzo-Ortega H, Kay L, Woolacott N, Palmer S. Tumour necrosis factor-inhibitors for ankylosing spondylitis and non-radiographic axial spondyloarthritis: a systematic review and economic evaluation. Health Technology Assessment 2016;20(9).

Hinde S, Wade R, Palmer S, Woolacott N, Spackman E. Apremilast for the treatment of moderate to severe plaque psoriasis: A critique of the evidence. PharmacoEconomics 2016;doi:10.1007/s40273-016-0382-3.

Llewellyn A, Faria R, Woods B, Simmonds M, Lomas J, Woolacott N, Griffin S. Daclatasvir for the treatment of chronic hepatitis C: A critique of the clinical and economic evidence. PharmacoEconomics 2016;34(10):981-992.

Lomas J, Llewellyn A, Soares M, Simmonds M, Wright K, Eastwood A, Palmer S. The clinical and cost effectiveness of Vortioxetine for the treatment of a major depressive episode in patients with failed prior antidepressant therapy: A critique of the evidence. PharmacoEconomics 2016;34(9):901-912.

Sideris E, Corbett M, Palmer S, Woolacott N, Bojke L. The clinical and cost effectiveness of Apremilast for treating active psoriatic arthritis: A critique of the evidence. Pharmacoeconomics 2016 doi:10.1007/s40273-016-0419-7.

Woods B, Faria R, Griffin S. Assessing the value of new treatments for Hepatitis C: Are international decision makers getting this right? PharmacoEconomics 2016;34(5):427-433.

2015

Claxton K, Sculpher M, Palmer S, Culyer AJ. Causes for concern: is NICE failing to uphold its responsibilities to all NHS patients? Health Economics 2015;24(1):1–7.

Faria R, Hernandez Alava M, Manca A, Wailoo A. The use of observational data to inform estimates of treatment effectiveness in technology appraisal: methods for comparative individual patient data. NICE DSU technical support document 17;2015.

Giannopoulou C, Sideris E, Wade R, Moe-Byrne T, Eastwood A, McKenna C. Ipilimumab for previously untreated unresectable malignant melanoma: a critique of the evidence. PharmacoEconomics 2015;33(12):1269-1279.

Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E. The clinical and cost effectiveness of aflibercept in combination with irinotecan and fluorouracil-based therapy (FOLFIRI) for the treatment of metastatic colorectal cancer which has progressed following prior oxaliplatin-based chemotherapy: a critique of the evidence. Pharmacoeconomics 2015;33(5):457-466.

Wade R, Sideris E, Paton F, Rice S, Palmer S, Fox D, Woolacott N, Spackman E. Graduated compression stockings for the prevention of deep-vein thrombosis in postoperative surgical patients: a systematic review and economic model with a value of information analysis. Health Technology Assessment 2015;19(98).

2014

Faria R, McKenna C, Palmer S. Optimizing the position and use of omalizumab for severe persistent allergic asthma using cost-effectiveness analysis. Value in Health 2014;17(8): 772-782.

Hinde S, Soares M, Burch J, Marson A, Woolacott N, Palmer S. The added clinical and economic value of diagnostic testing for epilepsy surgery. Epilepsy Research 2014;108(4)775-781.

2013

Faria R, McKenna C, Wade R, Yang H, Woolacott N, Sculpher M. The EOS 2D/3D X-ray imaging system: A cost-effectiveness analysis quantifying the health benefits from reduced radiation exposure. European Journal of Radiology 2013;82(8):e342-e349.

Faria R, Spackman E, Burch JA, Corbacho Martin MB, Todd D, Pepper C, Woolacott NF, Palmer S. Dabigatran for the prevention of stroke and systemic embolism in atrial fibrillation: a NICE single technology appraisal. Pharmacoeconomics 2013;31(7):551-562.

Norman G, Faria R, Paton F, Llewellyn A, Fox D, Palmer S, Clifton I, Paton J, Woolacott N, McKenna C. Omalizumab for the treatment of severe persistent allergic asthma: a systematic review and economic evaluation. Health Technology Assessment 2013;17(52):1–342.

Spackman E, Rice S, Norman G, Suh D-C, Eastwood A, Palmer S. Trastuzumab for the treatment of HER2-positive metastatic gastric cancer:A NICE single technology appraisal. Pharmacoeconomics 2013;31(3):185-194.

Wade R, Spackman E, Corbett M, Walker S, Light K, Naik R, Sculpher M, Eastwood A. Adjunctive colposcopy technologies for examination of the uterine cervix – DySIS, LuViva advanced cervical scan and niris imaging system. Health Technology Assessment 2013;17(8)

2012

Burch J, Griffin S, McKenna C, Walker S, Paton J, Wright K, Woolacott N. Omalizumab for the treatment of severe persistent allergic asthma in children Aged 6-11 years: a NICE single technology appraisal. Pharmacoeconomics 2012;30(11):991-1004.

Burch J, Hinde S, Palmer S, Beyer F, Minton J, Marson A, Wieshmann U, Woolacott N, Soares M. The clinical and cost-effectiveness of technologies used to visualise the seizure focus in people with refractory epilepsy being considered for surgery: a systematic review and decision-analytical model. Health Technology Assessment 2012;16(34).

McKenna C, Maund E, Sarowar M, Fox D, Stevenson M, Pepper C, Woolacott N, Palmer S. Dronedarone for the treatment of atrial fibrillation. A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:35-46.

McKenna C, Wade R, Faria R, Yang H, Stirk L, Gummerson N, Sculpher M, Woolacott N. EOS 2D/3D X-ray imaging system: a systematic review and economic evaluation. Health Technology Assessment 2012;16(14):1-188.

McKenna C, Walker S, Lorgelly P, Fenwick E, Burch J, Suekarran S, Bakhai A, Witte K, Harden M, Wright K, Woolacott N, Palmer S. Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart failure. Value in Health 2012;15(3).

Rodgers M, Asaria M, Walker S, McMillan D, Lucock M, Harden M, Palmer S, Eastwood A. The clinical effectiveness and cost-effectiveness of low-intensity psychological interventions for the secondary prevention of relapse after depression: a systematic review. Health Technology Assessment 2012;16(28):1-129.

Yang H, Craig D, Epstein D, Bojke L, Light K, Bruce I, Sculpher M, Woolacott N. Golimumab for the treatment of psoriatic arthritis: A NICE Single Technology Appraisal. Pharmacoeconomics 2012;30:257-70.